Zydus Lifesciences rises on getting final nods for Dexamethasone Tablets
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
Zydus Lifesciences is currently trading at Rs. 808.40, up by 6.55 points or 0.82% from its previous closing of Rs. 801.85 on the BSE.
The scrip opened at Rs. 805.00 and has touched a high and low of Rs. 809.85 and Rs. 802.00 respectively. So far 2090 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 809.85 on 09-Feb-2024 and a 52 week low of Rs. 452.20 on 27-Feb-2023.
Last one week high and low of the scrip stood at Rs. 809.05 and Rs. 754.00 respectively. The current market cap of the company is Rs. 81163.59 crore.
The promoters holding in the company stood at 74.98%, while Institutions and Non-Institutions held 18.03% and 6.99% respectively.
Zydus Lifesciences has received final approvals from the United States Food and Drug Administration (USFDA) to manufacture and market Dexamethasone Tablets USP, 0.5 mg, 0.75 mg, 1.5 mg, 4 mg and 6 mg (USRLD: Decadron Tablets) and Dexamethasone Tablets USP, 2 mg (USRLD: Dexamethasone Tablets).
Dexamethasone is used to treat a number of different conditions, such as inflammation (swelling), severe allergies, adrenal problems, arthritis, asthma, blood or bone marrow problems, kidney problems, skin conditions, and flare-ups of multiple sclerosis. The products will be manufactured at the group’s formulation manufacturing facility at Baddi, Himachal Pradesh.
Dexamethasone Tablets USP, 0.5 mg, 0.75 mg, 1.5 mg, 4 mg and 6 mg had annual sales of $22 million and Dexamethasone Tablets USP, 2 mg has annual sales of $6 million in the United States (IQVIA Dec. Nov. 2023). The group now has 386 approvals and has so far filed over 448 ANDAs since the commencement of the filing process in FY 2003-04.
Zydus Lifesciences (formerly known as Cadila Healthcare) is an India-based pharmaceutical company.
